Show simple item record

Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer

dc.contributor.authorDemir, G.
dc.contributor.authorSeber, S.
dc.contributor.authorKorkmaz, T.
dc.contributor.authorAydin, K.
dc.contributor.authorBozkurt, M.
dc.contributor.authorAkun, E.
dc.contributor.authorTecimer, C.
dc.contributor.authorOkutur, K.
dc.contributor.authorHasbal, B.
dc.contributor.authorNamal, E.
dc.date.accessioned2021-03-03T10:21:42Z
dc.date.available2021-03-03T10:21:42Z
dc.date.issued2012
dc.identifier.citationAkun E., Okutur K., Seber S., Korkmaz T., Aydin K., Bozkurt M., Namal E., Hasbal B., Tecimer C., Demir G., "Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer", JOURNAL OF BUON, cilt.17, sa.4, ss.669-676, 2012
dc.identifier.issn1107-0625
dc.identifier.othervv_1032021
dc.identifier.otherav_222b9e63-e9a7-4351-b72b-6de1fd3b79ac
dc.identifier.urihttp://hdl.handle.net/20.500.12627/27989
dc.description.abstractPurpose: To determine the clinical features of bevacizumab-associated toxicities in metastatic colorectal cancer (MCRC) patients.
dc.language.isoeng
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.titleSafety and tolerability of first-line bevacizumab in metastatic colorectal cancer
dc.typeMakale
dc.relation.journalJOURNAL OF BUON
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume17
dc.identifier.issue4
dc.identifier.startpage669
dc.identifier.endpage676
dc.contributor.firstauthorID206357


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record